Atlas Trials

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Clinical trial NCT06163040 · COMPLETED

Trial details

NCT number
NCT06163040
Sponsor
Bristol-Myers Squibb
Status
COMPLETED
Study type
OBSERVATIONAL
Relapsed or Refractory Multiple Myeloma
Start date
2023-12-22
Primary completion
2025-03-17
Enrollment
7

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.